Literature DB >> 26562685

Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.

Shinichi Mochizuki1, Hiromi Morishita2, Kouji Kobiyama3, Taiki Aoshi4, Ken J Ishii3, Kazuo Sakurai5.   

Abstract

The induction of antigen-specific immune responses requires immunization with not only antigens, but also adjuvants. CpG oligonucleotides (CpG-ODNs) are well-known ligands for Toll-like receptor 9 and a potent adjuvant that induces both Th1-type humoral and cellular immune responses including cytotoxic T-lymphocyte responses. We previously demonstrated that β-glucan schizophyllan (SPG) can form complexes with CpG-ODNs with attached dA40 (CpG-dA/SPG), which can accumulate in macrophages in the draining inguinal lymph nodes and induce strong immune responses by co-administration of antigenic proteins, namely ovalbumin (OVA). Immunization with antigenic peptides, OVA257-264, did not induce these antigen-specific immune responses even in combination with CpG-dA/SPG, indicating that peptides require a carrier to antigen presenting cells. In this study, we prepared conjugates comprising OVA257-264 and dA40, and made complexes with SPG. Immunization with OVA257-264-dA/SPG induced peptide-specific immune responses in combination with CpG-dA regardless of complexation with SPG both in vitro and in vivo. When splenocytes from immunized mice were incubated with E.G7-OVA tumor model cells presenting OVA peptides, the number of cells drastically decreased after 24h. Furthermore, mice pre-immunized with OVA257-264-dA/SPG and CpG-ODNs exhibited a long delay in tumor growth after tumor inoculation. Therefore, these peptide-dA/SPG and CpG-dA/SPG complexes could be used as a potent vaccine for the treatment of cancers and infectious diseases.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antigen presenting cell; Cancer vaccine; CpG-ODN; Peptide vaccine; β-Glucan

Mesh:

Substances:

Year:  2015        PMID: 26562685     DOI: 10.1016/j.jconrel.2015.11.008

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  3 in total

Review 1.  Using PAMPs and DAMPs as adjuvants in cancer vaccines.

Authors:  Huanyou Sun; Wenwen Hu; Yinan Yan; Zichun Zhang; Yuxin Chen; Xuefan Yao; Ling Teng; Xinyuan Wang; Dafei Chai; Junnian Zheng; Gang Wang
Journal:  Hum Vaccin Immunother       Date:  2021-09-14       Impact factor: 4.526

Review 2.  Carbohydrate Conjugates in Vaccine Developments.

Authors:  Shuyao Lang; Xuefei Huang
Journal:  Front Chem       Date:  2020-04-15       Impact factor: 5.221

3.  Application of red clover isoflavone extract as an adjuvant in mice.

Authors:  Hongbo Chen; Xue Zhang; Longsi Liu; Mingqin Cai; Zhijun Guo; Longxin Qiu
Journal:  Exp Ther Med       Date:  2019-12-11       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.